Mostrar el registro sencillo del ítem

dc.contributor.authorYohn, Samantha E.
dc.contributor.authorSanterre, Jessica L.
dc.contributor.authorNunes, Eric J.
dc.contributor.authorKozak, Rouba
dc.contributor.authorPodurgiel, Samantha J.
dc.contributor.authorCorrea, Merce
dc.contributor.authorSalamone, John
dc.date.accessioned2016-05-30T17:23:19Z
dc.date.available2016-05-30T17:23:19Z
dc.date.issued2015
dc.identifier.issn0091-3057
dc.identifier.issn1873-5177
dc.identifier.urihttp://hdl.handle.net/10234/160087
dc.description.abstractMesolimbic dopamine (DA), particularly in the nucleus accumbens, is a critical component of the brain circuitry involved in behavioral activation and effort-related processes. Although much is known about the characteristics of DA D2 receptor antagonism on effort-related choice behavior, less is known about the effects of D1 antagonism, and agonist/antagonist interactions. The highly selective D1 antagonist ecopipam was studied for its effects on effort-related choice behavior using the concurrent fixed ratio (FR) 5/chow feeding choice and T-maze barrier choice procedures. In rats tested on the FR5/chow feeding choice task, ecopipam shifted choice behavior, decreasing lever pressing for preferred high carbohydrate pellets but increasing consumption of lab chow. Also, ecopipam decreased selection of the high effort option (i.e., climbing the barrier to obtain a larger reward) in rats tested on the T-maze task, but did not disrupt arm preference or discrimination when no barrier was present. The D1 agonists SKF38393, SKF81297 and A77636 were assessed for their ability to reverse the effects of ecopipam, and in each case the D1 agonist significantly attenuated the effects of ecopipam, typically with an inverted-u shaped dose/response curve. SKF81297 also was able to reverse the effects of the catecholamine depleting agent tetrabenazine on T-maze performance. In summary, the present results implicate DA D1 receptors in the regulation of behavioral activation and effort-related functions, and demonstrate the utility of using tests of effort-related choice behavior for assessing the effects of D1 agonists.ca_CA
dc.description.sponsorShipThis work was supported by grants to J.S. from the National Institute of Mental Health (MH094966) and Pfizer, and to Merce Correa from Fundació Bancaixa/ U. Jaume I. (P1.1B2010-43). Many thanks to Christian Thompson for his assistance.ca_CA
dc.format.extent10 p.ca_CA
dc.language.isoengca_CA
dc.publisherElsevierca_CA
dc.relation.isPartOfPharmacology, Biochemistry and Behavior 135 (2015) 217–226ca_CA
dc.rights0091-3057/© 2015 Published by Elsevier Inc.ca_CA
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/*
dc.subjectDopamineca_CA
dc.subjectD1 receptorca_CA
dc.subjectNucleus accumbensca_CA
dc.subjectBehavioral activationca_CA
dc.subjectMotivationca_CA
dc.subjectDepressionca_CA
dc.subjectFatigueca_CA
dc.subjectAnergiaca_CA
dc.titleThe role of dopamine D1 receptor transmission in effort-related choice behavior: Effects of D1 agonistsca_CA
dc.typeinfo:eu-repo/semantics/articleca_CA
dc.identifier.doihttp://dx.doi.org/10.1016/j.pbb.2015.05.003
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccessca_CA
dc.relation.publisherVersionhttp://www.sciencedirect.com/science/article/pii/S0091305715001446ca_CA


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem